BIO Comments on FDA Draft Guidance on Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products
March 22, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products.
BIO supports the FDA’s efforts to update and replace the 1997 version of this guidance, and suggests the FDA revise the guidance entitled Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products, which is also dated July 1997.
BIO appreciates the inclusion of cellular, gene, and cell-based gene therapy products in the scope but notes some of these products are excluded as exceptions in certain examples in the appendix. BIO’s comments include suggested changes to promote the longevity of the guidance, make terminology more consistent, and promote continuity and consistency across various guidelines.
Download Full Comments Below
2018-03-22 BIO Comments On CMC Changes To Approved Application Certain Biological Products FINAL
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products.
BIO supports the FDA’s efforts to update and replace the 1997 version of this guidance, and suggests the FDA revise the guidance entitled Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products, which is also dated July 1997.
BIO appreciates the inclusion of cellular, gene, and cell-based gene therapy products in the scope but notes some of these products are excluded as exceptions in certain examples in the appendix. BIO’s comments include suggested changes to promote the longevity of the guidance, make terminology more consistent, and promote continuity and consistency across various guidelines.